Stephen Rozzo, PhD, associate vice president and head, Biologics Medical Affairs, Sun Pharma, North America, explains tildrakizumab’s mechanisms of action in the treatment of psoriasis and how the drug differs from other approved biologics.
The regulatory nature of tildrakizumab and its administration in office distinguish the drug from other approved biologics for psoriasis, said Stephen Rozzo, PhD, associate vice president and head, Biologics Medical Affairs, Sun Pharma, North America.
Transcript
What are the mechanisms of action for tildrakizumab in the treatment of psoriasis and how does the drug compare with other approved biologics?
The mechanism of action of tildrakizumab is not completely known, but it binds interleukin (IL)-23 p19 polypeptide, which is a pro-inflammatory molecule [that] regulates immune responses to inflammation.
It is distinct in the sense that among similar agents, it is administered by dermatologists in their offices. And for that reason, we can be sure that the patients actually get their medication as opposed to other agents administered at home.
There are other mechanisms of action for drugs that bind tumor necrosis factor and inhibit that pro-inflammatory molecule, and others that bind IL-17, a different cytokine that is pro-inflammatory. The distinction with IL-23 is its regulatory nature. In other words, it does not in itself induce inflammation as the other 2 molecules do; it regulates the response to stimuli.
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Insufficient Data, Disparities Plague Lung Cancer Risk Factor Documentation
September 24th 2023On this episode of Managed Care Cast, we speak with the senior author of a study published in the September 2023 issue of The American Journal of Managed Care® on the importance of adequate and effective lung cancer risk factor documentation to determine a patient's eligibility for screening.
Listen